PL2485593T3 - Kombinacja - Google Patents

Kombinacja

Info

Publication number
PL2485593T3
PL2485593T3 PL10822733T PL10822733T PL2485593T3 PL 2485593 T3 PL2485593 T3 PL 2485593T3 PL 10822733 T PL10822733 T PL 10822733T PL 10822733 T PL10822733 T PL 10822733T PL 2485593 T3 PL2485593 T3 PL 2485593T3
Authority
PL
Poland
Prior art keywords
combination
Prior art date
Application number
PL10822733T
Other languages
English (en)
Polish (pl)
Inventor
Melissa Dumble
Tona Gilmer
Rakesh Kumar
Sylvie Laquerre
Peter F Lebowitz
Shannon Renae Morris
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2485593T3 publication Critical patent/PL2485593T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL10822733T 2009-10-08 2010-10-08 Kombinacja PL2485593T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24980309P 2009-10-08 2009-10-08
EP10822733.1A EP2485593B1 (en) 2009-10-08 2010-10-08 Combination
PCT/US2010/051907 WO2011044414A1 (en) 2009-10-08 2010-10-08 Combination

Publications (1)

Publication Number Publication Date
PL2485593T3 true PL2485593T3 (pl) 2015-06-30

Family

ID=43857162

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10822733T PL2485593T3 (pl) 2009-10-08 2010-10-08 Kombinacja

Country Status (16)

Country Link
US (2) US8835450B2 (enExample)
EP (1) EP2485593B1 (enExample)
JP (1) JP2013507382A (enExample)
KR (1) KR20120100978A (enExample)
CN (1) CN102665418B (enExample)
AU (1) AU2010303363B2 (enExample)
BR (1) BR112012008271A2 (enExample)
CA (1) CA2777085A1 (enExample)
EA (1) EA022982B1 (enExample)
ES (1) ES2532026T3 (enExample)
IL (1) IL218999A (enExample)
MX (1) MX2012004139A (enExample)
PL (1) PL2485593T3 (enExample)
PT (1) PT2485593E (enExample)
WO (1) WO2011044414A1 (enExample)
ZA (1) ZA201202494B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104302275A (zh) * 2012-04-24 2015-01-21 葛兰素史密斯克莱知识产权（第2号）有限公司 类固醇反应性皮肤病的治疗方法
AU2013334945A1 (en) * 2012-10-22 2015-04-23 Novartis Ag Combination
BR112015008924A2 (pt) * 2012-10-22 2017-07-04 Glaxosmithkline Llc combinação
CN104109159A (zh) 2013-04-17 2014-10-22 杭州普晒医药科技有限公司 苯磺酰胺噻唑化合物的新晶型及其制备方法
CN104540822B (zh) * 2013-07-08 2016-08-31 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的晶型及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE309205T1 (de) * 1999-01-13 2005-11-15 Warner Lambert Co Benzenesulfonamid-derivative und ihre verwendung als mek-inhibitoren
IL149150A0 (en) * 1999-11-22 2002-12-01 Smithkline Beecham Plc 2-(4-(6-methoxy-naphthalene-2-yl)-5-pyridin-4-yl-1h-imidazole-2-yl)-2-methyl-derivatives, pharmaceutical compositions comprising them and use thereof as tie2 receptor kinase inhibitors
WO2004080972A1 (en) * 2003-03-12 2004-09-23 Vertex Pharmaceuticals Incorporated Pirazole modulators of atp-binding cassette transporters
DE102004018198A1 (de) * 2004-04-15 2005-11-03 Merck Patent Gmbh Sulfonamide
WO2005121142A1 (en) * 2004-06-11 2005-12-22 Japan Tobacco Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido’2,3-d! pyrimidine derivatives and related compounds for the treatment of cancer
EP1981884B1 (en) * 2006-01-18 2012-06-13 Amgen, Inc Thiazole compounds as protein kinase b (pkb) inhibitors
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds

Also Published As

Publication number Publication date
EA201270526A1 (ru) 2012-12-28
CN102665418A (zh) 2012-09-12
JP2013507382A (ja) 2013-03-04
WO2011044414A1 (en) 2011-04-14
CN102665418B (zh) 2014-10-29
EP2485593B1 (en) 2015-01-07
IL218999A0 (en) 2012-06-28
US8835450B2 (en) 2014-09-16
AU2010303363A1 (en) 2012-04-26
US9402846B2 (en) 2016-08-02
BR112012008271A2 (pt) 2015-09-22
AU2010303363B2 (en) 2013-09-05
MX2012004139A (es) 2012-09-07
US20120196886A1 (en) 2012-08-02
KR20120100978A (ko) 2012-09-12
EP2485593A4 (en) 2013-02-13
ZA201202494B (en) 2012-12-27
EP2485593A1 (en) 2012-08-15
CA2777085A1 (en) 2011-04-14
PT2485593E (pt) 2015-04-28
ES2532026T3 (es) 2015-03-23
EA022982B1 (ru) 2016-04-29
IL218999A (en) 2015-08-31
US20140350039A1 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
ZA201202612B (en) Combination
EP2462514A4 (en) GREEN BOOKS
EP2515891A4 (en) 3-keto-N-propargyl-1-aminoindan
IL219103A0 (en) Combination
IL219786A0 (en) Combination
ZA201202494B (en) Combination
ZA201202173B (en) Combination
ZA201202495B (en) Combination
ZA201202258B (en) Combination
IL218801A0 (en) Combination
GB0903227D0 (en) Fructanase
GB0900568D0 (en) Poymerisation
GB0901391D0 (en) Combination
GB0906696D0 (en) Combination
GB0921334D0 (en) Preferred combination
GB0906221D0 (en) Shu-sy
GB0900362D0 (en) Hipestone
GB0914413D0 (en) Poly-tool
GB0900696D0 (en) Waxpod
GB0905893D0 (en) Spacetent
GB0901630D0 (en) BridgeEye
GB0902622D0 (en) Teresa-2
AU2009190V (en) SILSUN Chrysocephalum apiculatum
AP2009000324S (en) Rudpak
AP00242S1 (en) Woodstove